5.95
-0.05
(-0.83%)
At close: 8:19:31 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
43,472.17
43,472.17
--
65.41
190.94
Cost of Revenue
3,190.53
3,190.53
--
3.73
148.94
Gross Profit
40,281.64
40,281.64
--
61.67
42
Operating Expense
62,638.03
62,638.03
48,957.79
30,685.64
29,479.58
Operating Income
-22,356.39
-22,356.39
-48,957.79
-30,623.97
-29,437.59
Net Non Operating Interest Income Expense
2,542.39
2,542.39
2,647.56
299.50
-1.54
Other Income Expense
489.21
489.21
-28.99
37.15
-21.29
Pretax Income
-19,324.79
-19,324.79
-46,339.23
-30,287.32
-29,460.41
Tax Provision
-1,394.77
-1,394.77
--
-585.62
-1,250.19
Net Income Common Stockholders
-17,930.02
-17,930.02
-46,339.23
-29,701.71
-28,210.23
Diluted NI Available to Com Stockholders
-17,930.02
-17,930.02
-46,339.23
-29,701.71
-28,210.23
Basic EPS
-0.80
-0.30
-0.91
-0.74
-0.75
Diluted EPS
-0.80
-0.30
-0.91
-0.74
-0.75
Basic Average Shares
57,855.89
58,871.58
50,902.93
40,274.27
37,666.08
Diluted Average Shares
57,855.89
58,871.58
50,902.93
40,274.27
37,666.08
Total Operating Income as Reported
-22,356.39
-22,356.39
-48,957.79
-30,623.97
-29,437.59
Total Expenses
65,828.56
65,828.56
48,957.79
30,689.38
29,628.52
Net Income from Continuing & Discontinued Operation
-17,930.02
-17,930.02
-46,339.23
-29,701.71
-28,210.23
Normalized Income
-17,901.45
-17,901.45
-46,310.23
-29,738.14
-28,189.83
Interest Income
2,578.79
2,578.79
2,681.85
326.02
14.40
Interest Expense
36.41
36.41
34.30
26.52
15.94
Net Interest Income
2,542.39
2,542.39
2,647.56
299.50
-1.54
EBIT
-19,288.39
-19,288.39
-46,304.93
-30,260.81
-29,444.47
EBITDA
-18,978.60
-18,978.60
-46,234.18
-30,176.19
-29,382.58
Reconciled Cost of Revenue
3,190.53
3,190.53
--
3.73
148.94
Reconciled Depreciation
309.78
309.78
70.76
84.62
61.89
Net Income from Continuing Operation Net Minority Interest
-17,930.02
-17,930.02
-46,339.23
-29,701.71
-28,210.23
Total Unusual Items Excluding Goodwill
-30.79
-30.79
-28.99
37.15
-21.29
Total Unusual Items
-30.79
-30.79
-28.99
37.15
-21.29
Normalized EBITDA
-18,947.82
-18,947.82
-46,205.18
-30,213.33
-29,361.29
Tax Rate for Calcs
0
0
--
0
0
Tax Effect of Unusual Items
-2.22
-2.22
--
0.71
-0.89
12/31/2021 - 5/9/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ARDX.MX Ardelyx, Inc.
105.50
0.00%
B9A.F BioArctic AB (publ)
14.93
+1.50%
RPD.MU Royalty Pharma plc
28.20
0.00%
2HA.F Spero Therapeutics, Inc.
0.5290
+6.55%
05Y.MU Vivoryon Therapeutics NV
1.8260
-0.87%
PROT Proteonomix, Inc.
0.0000
-90.00%
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+12.29%
HQ1.MU Oruka Therapeutics Inc. R
6.65
+3.91%
7PO.F Poxel S.A.
0.5090
-3.96%
P0F.F Egetis Therapeutics AB (publ)
0.3100
-5.20%